Pfizer Anticipates ‘Fair’ Share Of Adalimumab Market In US
Company Expects To Use Interchangeability Designation To Its Advantage
Pfizer expects to make significant strides in the adalimumab market once it launches its Humira biosimilar late next year, but may not be able to enjoy its anticipated interchangeability designation until 2024.
